Longitudinal mutational analysis in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the majic-ET study מאת O'Sullivan, J, Hamblin, A, Panchal, A, Yap, C, Fox, S, Alimam, S, Dreau, H, Howard, K, Ware, P, Baker, S, Cross, N, McMullin, M, Harrison, C, Mead, A

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib מאת O'Sullivan, JM, Hamblin, A, Yap, C, Fox, S, Boucher, R, Panchal A, Alimam, S, Dreau, H, Howard, K, Ware, P, Cross, NCP, McMullin, MF, Harrison, CN, Mead, AJ

Glucophosphate isomerase deficiency identified by next‐generation sequencing מאת Vora, S, Proven, M, Hipkiss, R, Ware, P, Howard, K, Dreau, H, Baird, S, Ouwehand, W, Megy, K, Stirrups, K, Lim, D, Norton, A, Kumar, A, Roberts, I, Layton, M, Roy, N

Combination of Deep Phenotyping and Targeted Next Generation Sequencing as a Diagnostic Tool in Children with Suspected MDS מאת Louka, E, Hamblin, A, Buck, G, Dreau, H, Ware, P, Ancliff, P, Baird, S, Bhatnagar, N, Campbell, H, Caswell, M, Connor, P, Gibson, B, Hall, G, Motwani, J, Norton, A, O'Connor, D, Patrick, K, Pinto, F, Wynn, R, Vora, A, Roberts, I, Mead, A, Rao, A